: 2



- 24. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 11.
- 25. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 12.
- 26. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 29.
- 27. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 33.
- 28. The protein C or activated protein C polypeptide of claim 23, wherein said at least one amino acid substitution is at residue 34.
- 29. A protein C or activated protein C polypeptide comprising a modified GLA domain, said modified GLA domain comprising three amino acid substitutions at positions selected from the group consisting of residues 11, 12, 29, 33 and 34.
- 30. The protein C or activated protein C polypeptide of claim 29, wherein said three amino acid substitutions are at residues 12, 33 and 34.
- 31. The protein C or activated protein C polypeptide of claim 30, wherein residue 33 is glutamic acid.
- 32. The protein C or activated protein C polypeptide of claim 30, wherein residue 34 is aspartic acid.
- 33. The protein C or activated protein C polypeptide of claim 30, wherein residue 33 is glutamic acid and residue 34 is aspartic acid.

ge : 3



- 34. The protein C or activated protein C polypeptide of claim 29, wherein residue 11 is glutamine.
- 35. A pharmaceutical composition comprising said protein C or activated protein C polypeptide of any one of claims 23-34 and a pharmaceutically acceptable carrier.
- 36. The composition of claim 35 for use in treating thrombosis in a mammal.
- 37. The composition of claim 35 for use in decreasing clot formation in a mammal.
- 38. The composition of claim 36, wherein said composition is formulated for parenteral administration to a human patient.
- 39. The composition of claim 37, wherein said composition is formulated for parenteral administration to a human patient.
- 40. An isolated nucleic acid, said nucleic acid comprising a nucleic acid sequence encoding said protein C or activated protein C polypeptide of claim 23 or claim 29.
- 41. A method of producing the protein C or activated protein C polypeptide of any one of claims 23-34, said method comprising expressing an isolated nucleic acid encoding said protein C or activated protein C polypeptide in a mammalian host cell.
- 42. The method of claim 40, wherein said mammalian host cell is an adenovirus-transfected human kidney 293 cell.--

APP3